Protagen’s thought-leaders and experts regularly contribute technical and opinion articles to some of the industry’s most respected editorial publications, on the topics of autoimmune disease and immuno-oncology.
Featured article: In our latest piece, Georg provides insights into how autoantibodies are already proving to be the biomarker class of choice for predicting immune-related Adverse Events (irAEs) in patients undergoing cancer immunotherapy, helping us to realise a future of safer and more effective treatment. Take a look at the full article here!
- Predicting the Future of Cancer Immunotherapy: Using Autoantibody Biomarkers to Drive Safer and More Effective Treatments; World Pharma Today; Nov 2018 (external link)
- Antibodies in Drug Discovery: Identifying Novel Biomarkers to Overcome Sjögren’s Syndrome; Technology Networks; Aug 2017 (external link)
- Monitoring the Balance between Immune Repression and Stimulation in Cancer Immunotherapy; Drug Discovery World; Jul 2017 (external link)
- Protagen is Taking Biomarkers from the Bench to the Bedside; xMAP® Insights; Jul 2017 (external link)
- Protagen and Luminex developing Biomarkers from the bench to the bedside; Nature; Jun 2017 (PDF)
- Personalised Immuno-Oncology; European Biopharmaceutical Review; Mar 2017 (PDF)
- Protagen identifies biomarkers in prostate cancer; DDN NEWS; May 2016 (print)
- Using Novel Concepts And Products For Autoimmune Diagnostics; Life Science Leader; Jan 2016 (external link)
- From Diagnostics to Companion Diagnostics – Targeting Autoimmune Diseases; Clinical Omics; Dec 2015 (external link)
- Defeating Lupus Starts With a Diagnosis; DDNews; Oct 2015 (PDF)
- Leading Provider of Autoimmune Diagnostic Products; Zillion; Oct 2015 (PDF)
- A Multi-marker Approach to Diagnosing Autoimmune Diseases; Medical Laboratory Observer; Oct 2015 (PDF)
- From ‘Omics’ Biomarker Discovery to Novel Clinical Tests Strategies and Challenges; Sep 2015 (external link)
- Innovative Diagnostik für Autoimmunerkrankungen; TZDo News; Aug 2015 (external link)
- Protagen AG – Testing Patients; European Biopharmaceutical Review; Jul 2015 (PDF)
- Autoimmune diseases and the power of separation; The Journal of Precision Medicine; Mar 2015 (external link)
- Neue Ansätze für die Personalisierte Medizin; TZDOnews; Mar 2015 (PDF)
- Protagen – Serie Mensch und Unternehmen; Transkript; Mar 2015 (PDF)
- Publikation – Seltene Krankheiten; Reflex Verlag; Mar 2015 (PDF)
- In Autoimmune Disease, Finding Clarity Beyond the Genome: Stefan Muellner, Protagen AG; Mendelspod; Feb 2015 (external link)
- Protagen Raises EUR4M for Serum Diagnostics; DOW JONES News Report; Jan 2015 (PDF)
- Neue CDx-Konzepte für Autoimmunkrankheiten; Stefan Müllner; Transkript; May 2014 (PDF)
- Erfolgreiche Autoimmuntherapien Erfordern Neue Entwicklungskonzepte für Companion Diagnostics; Stefan Müllner; Ernst & Young Biotech-Report; Mar 2014 (PDF)
As part of our mission to advance the treatment of cancer and autoimmune diseases, we have analyzed the immune responses of over 20,000 patients and healthy controls, leading to a unique, comprehensive, and permanently growing database.
Here you can see some of Protagen’s most recent conference presentations and posters, where the company’s latest advancements in disease research have been shared with delegates from around the world.
Here you will find a number of our visual resources that help explain some of the disease areas we work in, and the challenges we are overcoming. From animations to whitepapers and eBooks, see below for a number of downloadable resources.
Get in touch
Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.